Statement from American Society of Hematology President Janis A. Abkowitz, MD, on Congressional Agreement to Avoid the Fiscal Cliff

Statement from American Society of Hematology President Janis A. Abkowitz, MD, on Congressional Agreement to Avoid the Fiscal Cliff
Society Pleased About Immediate Protection for  Biomedical Research, Physician Reimbursement; Urges Congress to Protect Programs from Further Cuts & Next Cliff

(WASHINGTON, January 2, 2013) - As the world's largest professional society concerned with the causes and treatment of blood disorders, many of ASH's more than 14,000 members heavily rely on funding from the National Institutes of Health (NIH) to conduct cutting-edge research that results in cures and better treatments for millions of patients with blood diseases and cancer around the world. Thanks to congressional action late New Year's Day that delays the sequester for two months, our members' work to develop cures for some of America's most deadly diseases will not be interrupted today. The Society is also pleased that Congress has prevented the scheduled 27 percent cut to physician payment.

While the legislation passed protects the country from going over a fiscal cliff for the time being, the Society is keenly aware that NIH and other non-defense discretionary programs are not safeguarded from future cuts and there is not a permanent solution for the flawed physician payment formula. Given this uncertain outlook, ASH will continue to urge lawmakers to provide balanced deficit reduction that does not further cut discretionary programs like NIH.  The Society will educate Congress about the value of biomedical research so that all members of the new 113th Congress understand that this is not the time to defund science and that discoveries made possible by investments in NIH generate incredible returns in the form of lives and jobs and importantly help secure America's position as a global economic force.
For more information on ASH's campaign to fight for NIH funding, visit
The American Society of Hematology (ASH) ( is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (, the most cited peer-reviewed publication in the field, which is available weekly in print and online.

Andrea Slesinski, American Society of Hematology
[email protected]; 202-552-4927

Suggested Articles

The discovery that 500 cancers can be slotted into 10 subtypes, each of which is driven by a common set of proteins, could inspire new therapies.

Can an unexpected Sarepta win be good news for Biogen?

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.